Kymera Therapeutics, Inc.
KYMRNext catalyst
Phase 1 Results - KT-579
Get an email about KYMR's next catalysts
Track Kymera Therapeutics (KYMR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
KYMR Earnings Report
EPS Est: $-1.26 | FQ end Sep/2026 | Call: bmo
Phase 1 Results - KT-579
Kymera expects Phase 1 data for KT-579 in the second half of 2026 and targets completion of KT-621 BROADEN2 trial enrollment by year-end 2026.
KT-621 Phase 2 Est. Readout (BROADEN2)
Primary completion for KT-621 trial (NCT07217015) in Atopic Dermatitis
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KT-621 | Phase 2 | Atopic Dermatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Kymera Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Kymera Therapeutics, Inc.'s (KYMR) pipeline across Phase 2. Its lead program is KT-621 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kymera Therapeutics, Inc.'s next FDA catalyst?→
Kymera Therapeutics, Inc.'s (KYMR) next tracked catalyst is a Phase 1 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYMR biotech catalysts?→
Add KYMR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kymera Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.